Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs

Inclusion Criteria: * Completed the 96-week initial study period of PACTG P1024 and had enrolled into that study between June 1, 2001 and March 31, 2002 * Fulfilled PACTG P1024's definition of HAART (taking 3 or more antiretrovirals \[ARVs\] from at least 2 of the available therapeutic drug classes) during PACTG P1024's vaccination period (Weeks 0 to 24). Patients who were taking 3 nucleoside reverse transcriptase inhibitors during that period without a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor (PI) are not eligible for this study. Nontherapeutic boosting doses of ritonavir used in ritonavir-boosted PI regimens are not counted as separate ARVs. * Stable ARV regimen in the 4 weeks prior to study entry * No changes anticipated to current ARV regimen during this study * Willing to complete all study vaccinations and evaluations * Willing to use acceptable forms of contraception, if applicable * Parent or guardian willing to provide informed consent, if applicable Exclusion Criteria: * Abnormal blood or chemistry values on most recent laboratory tests. More information on this criterion can be found in the protocol. * Received PCV, HBV, PPV, or MMR vaccines during PACTG P1024 in a sequence other than specified in PACTG P1024 * Received one or more doses of each of PCV, PPV, MMR, or HBV vaccines since the end of PACTG P1024's vaccination period * Previous Grade 3 or higher adverse events or allergic reactions judged to be possibly or definitely related to the PCV, PPV, MMR, or HBV vaccines * Received any killed vaccine within the 4 weeks prior to study entry * Received any live vaccine within the 6 weeks prior to study entry * Planning to receive any killed or live vaccine other than study vaccines between the first and third study visits * Presence of an underlying condition that contraindicates use of any of the study vaccines. Patients who have a CD4% less than 15% will not be given the MMR vaccine, but such patients will not be excluded from this study. * Current immunomodulatory therapy, including IL-2, any interferon product, GM-CSF, or thalidomide. Patients taking G-CSF or erythropoietin are not excluded. * Anticipated need for immunomodulatory treatment during this study * Any intramuscular immune globulin product within the 6 months prior to study entry * Intravenous immune globulin within the 11 months prior to study entry * Platelets or plasma products within the 7 months prior to study entry * Anticipated need for immune globulin products during this study * Current systemic immunosuppressive therapy, including the equivalent of 1 mg/kg/day or greater of prednisone in the 2 weeks prior to study entry. Patients using inhaled corticosteroids only are not excluded from this study. More information on this criterion can be found in the protocol. * Anticipated need for systemic immunosuppressive therapy during this study * Other known or suspected diseases of the immune system * Cancer in the 3 months prior to study entry or treatment for cancer within the 3 months prior to study entry * Other acute or chronic medical or surgical conditions or contraindications that, in the opinion of the investigator, may interfere with the study * Known bleeding disorder * Any Grade 2 or higher clinical toxicity at study screening. More information on this criterion can be found in the protocol. * Require certain medications * Pregnancy